Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
Percutaneous closure of patent foramen ovale: “Closed” door after the last randomized trials?
Joel Hernandez, Raul Moreno, Department of Interventional Cardiology, University Hospital La Paz, 28045 Madrid, Spain
Author contributions: Hernandez J wrote the manuscript; Moreno R provided the idea, insight, statistical analysis and manuscript edition.
Correspondence to: Raul Moreno, MD, PhD, FESC, Department of Interventional Cardiology, University Hospital La Paz, Paseo La Castellana 261, 28045 Madrid, Spain. raulmorenog@hotmail.com
Telephone: +34-68-7483054 Fax: +34-68-7483054
Received: September 30, 2013
Revised: November 14, 2013
Accepted: December 9, 2013
Published online: January 26, 2014
Processing time: 207 Days and 16.5 Hours
Revised: November 14, 2013
Accepted: December 9, 2013
Published online: January 26, 2014
Processing time: 207 Days and 16.5 Hours
Core Tip
Core tip: Percutaneous patent foramen ovale (PFO) closure has been used for the prevention of recurrent cryptogenic stroke on the basis of observational studies; however, recent randomized trials do not support its use for this indication. A detailed analysis of these randomized trials could suggest that when the Amplatzer PFO Occluder is used, the risk of stroke is reduced.